EGFR and colorectal carcinoma: These findings, besides providing important aspects of CRC pathogenesis, also contributed to the development of novel therapeutic targets (e.g., anti-VEGF and anti-EGFR monoclonal antibodies [5]) and patient stratification strategies [6].